menu
    • menu
    [{"orgOrder":0,"company":"Anodyne Nanotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Anodyne Nanotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Anodyne Nanotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Anodyne Nanotech \/ Inapplicable"},{"orgOrder":0,"company":"Anodyne Nanotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ANN-102","moa":"Apelin receptor","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Anodyne Nanotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Transdermal Microneedle Patch","sponsorNew":"Anodyne Nanotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Anodyne Nanotech \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Anodyne Nanotech

    Menu

    Anodyne Nanotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Anodyne Nanotech

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Anodyne Nanotech

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANN-102

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anodyne Nanotech Advances New Therapy to Combat Sarcopenia

                            Details : ANN-102 is an APJ receptor agonist, currently being investigated for the treatment of sarcopenia.

                            Product Name : ANN-102

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 09, 2025

                            Lead Product(s) : ANN-102

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Anodyne Nanotech

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Anodyne Nanotech

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anodyne Nanotech Achieves Breakthrough in Transdermal Delivery of GLP-1 Drugs

                            Details : HeroPatch (semaglutide) is a trandermal patch which delivers glucagon-like peptide-1 (GLP-1) receptor agonist indicated for type 2 diabetes.

                            Product Name : HeroPatch

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            December 19, 2024

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth